| Home | Generics | Biosimilars | Docs & Positions | Facts & Figures | Press Room | Conferences | Links |
Making Medicines affordable.News RoomLatest NewsPress ReleasesReleases 2012Releases 2011Releases 2010Releases 2009Releases 2008Releases 2007 Releases 2006 Releases 2005 Releases 2004 Media KitHandy Info |
EGA News RoomLatest News from EGAPRESS RELEASE | Roma - Brussels, 27 January 2012 EUROPEAN COMMISSION AND MARIO MONTI’S GOVERNMENT SEEK TO INCREASE PATIENT ACCESS TO GENERIC MEDICINESThe European Generic medicines Association (EGA) together with the Italian association for generic medicines (ASSOGENERICI) welcome the European Commission’s formal call yesterday on Italy to comply with EU rules on the marketing authorisation of generic medicines. The European Commission infringement procedure started last year, following the EGA and ASSOGENERICI’s official complaint to the European Commission against the delays in granting market authorisation of generic medicines caused by incorrect linkage to intellectual property rights. More... PRESS RELEASE | Warsaw, 12 October 2011 NEW EGA PRESIDENT PROMOTES VALUE AND GLOBALISATIONMeeting today in Warsaw, the European Generic medicines Association’s Board announced the election of Gudbjorg Edda Eggertsdottir as its new President. Ms Eggertsdottir has been active in the generic medicines industry for over 30 years, witnessing the many challenges it has already faced on its way to becoming an essential part of the global healthcare offering. She has an impressive industry pedigree, which includes significant experience in the generic medicines sector in companies such as Actavis – where she is currently President Iceland, Strategic Projects – and Delta. Ms Eggertsdottir has been part of the EGA Executive Board for two years. More... PRESS RELEASE | Brussels, 11 October 2011 THE EUROPEAN GENERIC MEDICINES ASSOCIATION WELCOMES COMMISSION’S REVISED PROPOSALS ON INFORMATION TO PATIENTSThe European Generic medicines Association (EGA) welcomes the revised proposals on information to patients published today by the European Commission. The EGA sees this move as a constructive step forward as the proposals ensure a proper balance between improving access to information available from companies and preventing the exertion of undue commercial influence on patients, as advocated by MEPs in the proposition’s first reading. The proposals also emphasise the use of quality criteria for information to patients and the role of competent authorities in verifying and monitoring the information. More... PRESS RELEASE | Brussels, 22 June 2011 EGA MEMBER’S COMMITMENT REGARDING DCP SLOT BOOKING LAUNCHED AT CMD(h) MEETINGThe European Generic medicines Association (EGA) officially launched the code of conduct on slot booking for Marketing Authorisation Applications (MAA) as the generic medicines industry’s contribution to the process of improving the functioning of the EU regulatory system. More... PRESS RELEASE | Cascais, 17 June 2011 MAKING EUROPE THE MEDICINES MANUFACTURER OF THE WORLDEurope must seize on new opportunities to increase employment and create growth in the generic and biosimilar medicines markets. This was a key message delivered at the 17th Annual Conference of the European Generic medicines Association in Lisbon on 16-17 June 2011. More... PRESS RELEASE | 14 April 2011 EGA CALLS FOR AN EU INDUSTRIAL POLICY TO ENHANCE THE COMPETITIVENESS OF THE EU BIOSIMILAR MEDICINES INDUSTRY“There is a need for an EU industrial policy for the biosimilar medicines industry. The EGA will therefore continue to be at the forefront of the biosimilars debate working with EU and global policy makers” said Didier Barret, EGA President, in his opening address to the 9th EGA International Symposium on Biosimilar Medicines today in London. The EGA President welcomed the EU biosimilars’ framework which is operational and delivering, he also reminded the audience that biosimilar medicines have been safely in use for 5 years. More... PRESS RELEASE | 16 February 2011 EGA WELCOMES THE EUROPEAN PARLIAMENT VOTE ON FALSIFIED MEDICINES AND ANTICIPATES AN INTENSE IMPLEMENTATION PHASEThe European Generic medicines Association (EGA) welcomes today’s vote by Members of the European Parliament which seeks greater protection for EU patients by preventing the proliferation of falsified medicinal products in the EU. More... PRESS RELEASE | 25 January 2011 IMPROVEMENTS TO THE EU REGULATORY ENVIRONMENT WILL INCREASE PATIENT ACCESS TO GENERIC AND BIOSIMILAR MEDICINES AND ENHANCE COMPETITIVENESS AND COMPETITION"The EU regulatory environment needs to be optimised in order to deal with the growing demand for generic and biosimilar medicines. These medicines, which are now front-line treatments for a whole range of chronic diseases and account for nearly 50% of all medicines dispensed to European patients are the key to healthcare sustainability in the EU and the European regulatory system needs to reflect this reality." This was the key message of Greg Perry, Director General of the European Generic medicines Association (EGA), as he presented the association’s Vision 2015 at the EGA’s 10th Regulatory and Scientific Affairs Conference, held in London today. More...
EGA PublicationsEGA PUBLICATION | September 2010 EGA Conference Highlights | 07The key moments and messages from the EGA Annual Conference organised in June 2010 in Rome. EGA PUBLICATION | June 2010 EGA Conference Highlights | 06The key moments and messages from the conferences organised by the EGA during the first quarter of 2010. EGA PUBLICATION | September 2009 EGA Conference Highlights | 05The key moments and messages from the conferences organised by the EGA during the first half of 2009. EGA PUBLICATION | June 2009 EGA Conference Highlights | 04Competitive, Cost-Effective Generic Medicines Struggle to Overcome Major Hurdles: The key moments and messages from the conferences organised by the EGA during the first half of 2009. EGA PUBLICATION: January 2009 EGA Conference highlights | 03 [2755 Kb]European Generic Medicines Industry and Regulators Build
Dialogue for Increased Understanding & Cooperation EGA PUBLICATION: December 2008 EGA Conference highlights | 02 [315 Kb]“Mutual Trust and Commitment: Working Together Towards
Sustainable Healthcare for EU Citizens” EGA PUBLICATION: March 2008 EGA Conference highlights | 01 [260 Kb]“The EGA and EU Medicines Authorities Vow Joint Effort to Develop Greater Regulatory Efficiency for Generic Medicines” EGA PUBLICATION: September 2006 EGA FOCUS on Generic Medicines | 05 [750 Kb]• Missing Out on Generic Savings? • EGA in the Pharma Forum EGA PUBLICATION: April 2006 EGA FOCUS on Generic Medicines | 04 [1 Mb]• KUL Report on Measures to Promote Generics • Patent Linkage EGA PUBLICATION: November 2005 EGA FOCUS on Generic Medicines | 03 [1 Mb]• Pricing & Reimbursement • Ensuring Quality, Safety & Efficacy EGA PUBLICATION: February 2005 EGA FOCUS on Generic Medicines | 02 [700 Kb]• Fractured Markets • Sustainable Healthcare • Compulsory Licensing EGA PUBLICATION: December 2004 EGA FOCUS on Generic Medicines | 01 [700 Kb]• Paediatric Medicines • Generic Competition • Biogenerics EGA e-News ArchiveE-NEWS EGA e-News: 25 April 2005E-NEWS: EGA e-News: 15 March 2005Media KitComplete information about the EGA and its members designed to meet the needs of busy members of the press. Please check the Media Kit frequently for handy information and the latest news. Then feel free to contact EGA for any further questions you may have. |
EGA
Conference
|
| Copyright © 2004 EGA - European Generic medicines Association • • Cascading Pop-up Menus ©Angus Turnbull |